Please Wait
Applying Filters...
menu
    • menu
    Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-02-24

    Virtual Booth

    Contact Supplier

    Gentec Pharmaceutical Group is focused on manufacturing & developing APIs/HPAPIs, Advanced Intermediates & Fine Chemicals.

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-02-24

    Virtual Booth

    Contact Supplier

    Menu

    Nifurtimox

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    U.S. Food and Drug Administration Approves Lampit® (nifurtimox)
    U.S. Food and Drug Administration Approves Lampit® (nifurtimox)

    07 Aug 2020

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20200807005073/en

    BUSINESSWIRE
    07 Aug 2020
    Share Share
    Bayer's Phase III Clinical Trial Of Nifurtimox In Pediatric Patients
    Bayer's Phase III Clinical Trial Of Nifurtimox In Pediatric Patients

    15 Mar 2019

    // PRNECASWIRE.COM/NEWS-RELEASES/BAYERS-PHASE-III-CLINICAL-TRIAL-OF-NIFURTIMOX-IN-PEDIATRIC-PATIENTS-WITH-CHAGAS-DISEASE-MEETS-PRIMARY-ENDPOINT-300812233

    https://www.prnewswire.com/news-releases/bayers-phase-iii-clinical-trial-of-nifurtimox-in-pediatric-patients-with-chagas-disease-meets-primary-endpoint-300812233.html

    PRNECASWIRE.COM/NEWS-RELEASES/BAYERS-PHASE-III-CLINICAL-TRIAL-OF-NIFURTIMOX-IN-PEDIATRIC-PATIENTS-WITH-CHAGAS-DISEASE-MEETS-PRIMARY-ENDPOINT-300812233
    15 Mar 2019
    Share Share
    Bayer's PhIII Clinical Trial Of Nifurtimox In Pediatric Patients
    Bayer's PhIII Clinical Trial Of Nifurtimox In Pediatric Patients

    14 Mar 2019

    // BIOSPACE

    https://www.biospace.com/article/releases/bayer-s-phase-iii-clinical-trial-of-nifurtimox-in-pediatric-patients-with-chagas-disease-meets-primary-endpoint/

    BIOSPACE
    14 Mar 2019
    Share Share